![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bacchus Announces FDA Clearance for the TRELLIS-8 Catheter
Bacchus Announces FDA Clearance for the TRELLIS-8 Catheter
March 29, 2005
Bacchus Vascular has announced the recent FDA clearance of the TRELLIS-8 Peripheral Infusion System, an advanced drug infusion catheter designed for the treatment of deep vein thrombosis and arterial occlusions by enabling targeted delivery of clot-dissolving drugs.
The TRELLIS-8 is an advanced drug infusion catheter with two occluding balloons, drug infusion holes between the balloons and mechanical drug dispersion capabilities. This pharmacomechanical combination enables isolated thrombolysis, or targeted delivery and increased penetration of clot-dissolving drugs (thrombolytics) into a blood clot.
The TRELLIS-8 is introduced through a small percutaneous incision and is fully disposable. The clearance is for the infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct